These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 28526081)

  • 21. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.
    Slavin TP; Coffee B; Bernhisel R; Logan J; Cox HC; Marcucci G; Weitzel J; Neuhausen SL; Mancini-DiNardo D
    Cancer Genet; 2019 Jun; 235-236():31-38. PubMed ID: 31056428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
    Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
    Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.
    Byers H; Wallis Y; van Veen EM; Lalloo F; Reay K; Smith P; Wallace AJ; Bowers N; Newman WG; Evans DG
    Eur J Hum Genet; 2016 Nov; 24(11):1591-1597. PubMed ID: 27273131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
    Coppa A; Nicolussi A; D'Inzeo S; Capalbo C; Belardinilli F; Colicchia V; Petroni M; Zani M; Ferraro S; Rinaldi C; Buffone A; Bartolazzi A; Screpanti I; Ottini L; Giannini G
    Cancer Med; 2018 Jan; 7(1):46-55. PubMed ID: 29271107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample.
    Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S
    Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
    Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
    Kluska A; Balabas A; Paziewska A; Kulecka M; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2015 May; 8():19. PubMed ID: 25948282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
    Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
    ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.
    Castéra L; Krieger S; Rousselin A; Legros A; Baumann JJ; Bruet O; Brault B; Fouillet R; Goardon N; Letac O; Baert-Desurmont S; Tinat J; Bera O; Dugast C; Berthet P; Polycarpe F; Layet V; Hardouin A; Frébourg T; Vaur D
    Eur J Hum Genet; 2014 Nov; 22(11):1305-13. PubMed ID: 24549055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
    Balendran S; Liebmann-Reindl S; Berghoff AS; Reischer T; Popitsch N; Geier CB; Kenner L; Birner P; Streubel B; Preusser M
    J Neurooncol; 2017 Jul; 133(3):469-476. PubMed ID: 28497333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing.
    Terraf P; Pareja F; Brown DN; Ceyhan-Birsoy O; Misyura M; Rana S; O'Reilly E; Carlo MI; Aghajanian C; Liu Y; Derakhshan F; Jayakumaran G; Weigelt B; Walsh M; Stadler Z; Offit K; Ladanyi M; Robson M; Zehir A; Reis-Filho JS; Mandelker D
    Ann Oncol; 2022 Apr; 33(4):426-433. PubMed ID: 35074424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of BRCA1/2 large genomic rearrangement including BRCA1 promoter-region deletions using next-generation sequencing.
    Han E; Yoo J; Chae H; Lee S; Kim DH; Kim KJ; Kim Y; Kim M
    Clin Chim Acta; 2020 Jun; 505():49-54. PubMed ID: 32092317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
    Schulz E; Valentin A; Ulz P; Beham-Schmid C; Lind K; Rupp V; Lackner H; Wölfler A; Zebisch A; Olipitz W; Geigl J; Berghold A; Speicher MR; Sill H
    J Med Genet; 2012 Jul; 49(7):422-8. PubMed ID: 22652532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic testing for hereditary prostate cancer: Current status and limitations.
    Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
    Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
    Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing.
    Yamamoto Y; Kanai M; Kou T; Sugiyama A; Nakamura E; Miyake H; Yamada T; Nishigaki M; Kondo T; Murakami H; Torishima M; Matsumoto S; Kosugi S; Muto M
    J Hum Genet; 2020 Jan; 65(2):125-132. PubMed ID: 31628423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.
    Lee AJ; Cunningham AP; Tischkowitz M; Simard J; Pharoah PD; Easton DF; Antoniou AC
    Genet Med; 2016 Dec; 18(12):1190-1198. PubMed ID: 27464310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
    Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
    Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.